EHA / 15th Congress / Program overview per day /

SATELLITE SYMPOSIA


Thursday June 10, 2010


  Hall A Hall C Hall B Hall E Hall D
08:00 >     Genzyme Pfizer Pfizer
Oncology
10:00 >     Treatment options
in the management
of high-risk
adult Chronic
Lymphocytic
Leukaemia (CLL)
patients		 Implications
for Patient
Management:
Antifungal
Treatment in the
Haematology
Setting		 State of the art in MCL: new
therapeutic approaches are
complementing
established
treatments
           
10:45 >   PRIME
ONCOLOGY		 GENZYME NOVARTIS MSD
ONCOLOGY
12:45 >   Bridging the Gap
in the Management
of Hematologic
Malignancies		 The clinical need
for new options in
the management
of high-risk adult
AML patients		 Advances in
CML therapy:
highly selective
targeting, improved
response -
Interactive		 New Therapeutic
Targets in
Hematological
Malignancies
           
13:30 > F. HOFFMANN
- LA ROCHE		 ORTHO
BIOTECH		 CELGENE BRISTOL-MYERS
SQUIBB		 AMGEN
15:30 > MabThera:
Changing the
nature of
disease – CLL in
perspective		 Addressing
key clinical
questions in the
management of
multiple myeloma:
A scientifi c debate		 Optimising
outcomes in
haematological
malignancies:
recent advances
and future
directions		 Evolving concepts
in the management
of patients
newly-diagnosed
with CML		 State of the art in
haematological
malignancies –
applying the latest
clinical data to
           
16:15 > F. HOFFMANN
- LA ROCHE		 BOEHRINGER
INGELHEIM		 CELGENE NOVARTIS AMGEN
18:15 > The complete
treatment
approach in FL		 Transforming
the management
of venous and
arterial
thromboembolism		 New data and
new opportunities
in myeloma
treatment		 Benefits of iron
chelation therapy
in MDS: current
knowledge &
clinical experience		 The Big Question
What is the future
for ITP?
         
         
         
  Hall F Hall G Hall M Hall L
08:00 > MUNDIPHARMA SHIRE HOSPIRA SANDOZ
10:00 > Clinical case-study
conundrums in
the management
of indolent
lymphomas		 Ask the audience:
Make your
contribution to the
MPN management
challenge		 How should
we adjust
treatment for
older patients with
haematological
disorders?		 The role of
biosimilars in
improving
cancer care
         
10:45 > MUNDIPHARMA BRISTOL-MYERS
SQUIBB		 CEPHALON  
Webcast
12:45 > Can we improve
the outcome of
patients with high
risk of CNS
disease?		 Practical
considerations
in second-line
management of
chronic phase CML
patients in 2010		 Management of
haematological
malignancies and
of their infectious
complications		  
         
13:30 >   GLAXO-SMITHKLINE VIFOR
PHARMA		  
15:30 >   Current
Approaches in the
Management of
ITP: From Concept
to Consensus		 In the spotlight –
the role of I.V.
iron in the
treatment of
cancer patients		  
         
16:15 >   GLAXO-SMITHKLINE GENZYME  
18:15 >   Chronic
Lymphocytic
Leukemia:
Identifying
Challenges and
Evaluating
Solutions		 Optimising the
Diagnosis and
Treatment of
Aplastic Anemia